Compare Adaptive Biotechnologies Corp (ADPT) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Quanta Services Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Quanta Services Inc trades at $679 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 25× Adaptive Biotechnologies Corp's market cap, and Quanta Services Inc pays a 0.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PWR | |
|---|---|---|
Market Cap | $4.04B | $100.82B |
Sector | Health | Industrials |
52-Week High | $25.45 | $785.24 |
52-Week Low | $12.30 | $372.50 |
Enterprise Value | $4.10B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
PWR trades at $677.91, up 2.58% today, with strong technical momentum above key support at $664. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating expectations by 28%, revenue growth accelerating to $28.48B in 2025, and a record backlog supporting raised 2026 guidance. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $809.75 consensus target.
PWR offers compelling growth exposure to infrastructure demand, particularly in power and data centers, but faces valuation concerns with a P/E of 76.7x. Near-term risks include execution on large projects and macroeconomic sensitivity, while institutional accumulation and strong cash flow generation support the bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
